preoperative immunotherapy of malignant tumor相关文献:
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP.
BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674.
PMID:37253507
Breast Cancer Treatment.
Trayes KP, Cokenakes SEH.
Am Fam Physician. 2021 Aug 1;104(2):171-178.
PMID:34383430
Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.
Chaft JE, Shyr Y, Sepesi B, Forde PM.
J Clin Oncol. 2022 Feb 20;40(6):546-555. doi: 10.1200/JCO.21.01589. Epub 2022 Jan 5.
PMID:34985966
Immunosurveillance in clinical cancer management.
Kroemer G, Chan TA, Eggermont AMM, Galluzzi L.
CA Cancer J Clin. 2024 Mar-Apr;74(2):187-202. doi: 10.3322/caac.21818. Epub 2023 Oct 25.
PMID:37880100
Current opinions on diagnosis and treatment of adenoid cystic carcinoma.
Fang Y, Peng Z, Wang Y, Gao K, Liu Y, Fan R, Zhang H, Xie Z, Jiang W.
Oral Oncol. 2022 Jul;130:105945. doi: 10.1016/j.oraloncology.2022.105945. Epub 2022 Jun 2.
PMID:35662026
Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
Masarwy R, Kampel L, Horowitz G, Gutfeld O, Muhanna N.
JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):871-878. doi: 10.1001/jamaoto.2021.2191.
PMID:34473219
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.
Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Lordick Obermannová R, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Buges Sanchez C, Chau I, Lorenzen S, Daum S, Sinn M, Merelli B, van Grieken NCT, Nilsson M, Collienne M, Giraut A, Smyth E.
Ann Oncol. 2025 Feb;36(2):197-207. doi: 10.1016/j.annonc.2024.10.829. Epub 2024 Nov 13.
PMID:39542422
Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanoma.
Czarnecka AM, Ostaszewski K, Błoński P, Szumera-Ciećkiewicz A, Kozak K, Placzke J, Borkowska A, Terlecka A, Rogala P, Świtaj T, Sałamacha M, Mitręga-Korab B, Krotewicz M, Dudzisz-Śledź M, Rutkowski P.